Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.
The webcast of the presentation will be accessible or by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of HbF for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit and follow us on X and LinkedIn.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US lawmakers warn temporary CBDC ban isn’t enough, demand 'permanent' block

Expert: The Link Between Direct XRP Usage and Price Becomes More Distant
Stablecoins and the Changing Value of the Dollar
Top crypto news this week: Pi Network, Polkadot, US inflation data
